COARE Biotechnology

COARE Biotechnology is focused on developing treatments for tumor-initiating cells in solid tumor cancers.

Their research approach is focused on targeting tumor-initiating cells in solid tumor cancers. They utilize novel markers of tissue stem/progenitor cells as therapeutic targets. Utilizing tumor xenograft models created with human cancer cell lines, they have tested efficacy of our lead compounds. We have also developed a novel proprietary mouse cancer stem cell line that produces aggressive isograft tumors in immunodeficient mice. These tumors exhibit both epithelial and stromal features and tend to develop early metastases. We hypothesize that candidate therapeutics active against these isografts are also likely to be effective in human tumors, which share similar features. The ability to generate and isolate tumor-initiating cells has enabled COARE to accurately predict the response of these cells to investigational compounds, either alone or in combination. These studies have given COARE the unique opportunity to assess the importance of specific target proteins and RNAs in both animal and human cancers. Furthermore this research approach has uncovered novel regulatory mechanisms associated with biological pathways that control cancer stem cell fate and plasticity. In addition to our proprietary siRNA mediated delivery platform, COARE is also developing panels of monoclonal antibodies against key stem cell signaling molecules expressed in tumor initiating cells. COARE’s continued dedication to advancing the science of stem cell biology has lead to an extensive pipeline of agents targeting multiple pathways and designed to eventually eradicate solid tumor cancer morbidity and mortality with the hope of ending the suffering of patients and families worldwide.